Leukemia Research
Volume 26, Issue 11 , Pages 975-976 , November 2002

Clinical significance of interleukin-18

References 

  1. Okamura H, Tsutsi H, Komatsu T, Yutsudo M, Hakura A, Tanimoto T, et al.  Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature. 1995;378:88
  2. Lebel-Binay S, Berger A, Zinzindohoue F, Cugnenc P, Thiounn N, Fridman WH, et al.  Interleukin-18: biological properties and clinical implications. Eur. Cytokine. Netw. 2000;11:15
  3. Dinarello CA. Interleukin-18. Methods. 1999;19:121
  4. Pages F, Berger A, Lebel-Binay S, Zinzindohoue F, Danel C, Piqueras B, et al.  Proinflammatory and antitumor properties of interleukin-18 in the gastrointestinal tract. Immunol. Lett. 2000;75:9
  5. Dinarello CA. Interleukin-18, a proinflammatory cytokine. Eur. Cytokine. Netw. 2000;11:483
  6. Pizarro TT, Michie MH, Bentz M, Woraratanadharm J, Smith MF, Foley E, et al.  IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn’s disease: expression and localization in intestinal mucosal cells. J. Immunol. 1999;162:6829
  7. Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H. Interleukin-18 regulates both Th1 and Th2 responses. Annu. Rev. Immunol. 2001;19:423
  8. Zhang B, Wang Y, Zheng G-G, Ma X-T, Li G, Zhang F-K, Wu K-F. Clinical significance of IL-18 gene over-expression in AML. Leuk Res 2002;26:887.
  9. Lowenberg B. Prognostic factors in acute myeloid leukaemia. Best Pract. Res. Clin. Haematol. 2001;14:65
  10. Mrozek K, Heinonen K, Bloomfield CD. Prognostic value of cytogenetic findings in adults with acute myeloid leukemia. Int. J. Haematol. 2000;72:261
  11. Takubo T, Kumura T, Nakao T, Nakamae H, Aoyama Y, Nishiki S, et al.  Comparative study on complete remission rate and overall survival in three groups classified based on the serum interleukin-18 level in non-Hodgkin’s lymphoma patients. Acta Haematol. 2000;104:220
  12. Takada H, Ohga S, Mizuno Y, Suminoe A, Matsuzaki A, Ihara K, et al.  Oversecretion of IL-18 in haemophagocytic lymphohistiocytosis: a novel marker of disease activity. Br. J. Haematol. 1999;106:182
  13. Amo Y, Ohta Y, Hamada Y, Katsuoka K. Serum levels of interleukin-18 are increased in patients with cutaneous T-cell lymphoma and cutaneous natural killer-cell lymphoma. Br. J. Dermatol. 2001;145:674
  14. Merendino RA, Gangemi S, Ruello A, Bene A, Losi E, Lonbardo G, et al.  Serum levels of interleukin-18 and sICAM-1 in patients affected by breast cancer: preliminary considerations. Int. J. Biol. Markers. 2001;16:126
  15. Kohka H, Yoshino T, Iwagaki H, Sakuma I, Tanimoto T, Matsuo Y, et al. Interleukin-18/interferon-gamma-inducing factor, a novel cytokine, up-regulates ICAM-1 (CD54) expression in KG-1 cells. J Leukoc Biol 1998;64:519.
  16. Ohtsuki T, Micallef MJ, Kohno K, Tanimoto T, Ikeda M, Kurimoto M. Interleukin 18 enhances Fas ligand expression and induces apoptosis in Fas-expressing human myelomonocytic KG-1 cells. Anticancer Res. 1997;17:3253
  17. Golab J. Interleukin 18—interferon-γ inducing factor—a novel player in tumour immunotherapy?. Cytokine. 2000;12:332

PII: S0145-2126(02)00067-X

Leukemia Research
Volume 26, Issue 11 , Pages 975-976 , November 2002

Article Tools